MCID: HML002
MIFTS: 62

Hemolytic Anemia malady

Categories: Blood diseases, Immune diseases, Rare diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Hemolytic Anemia

Aliases & Descriptions for Hemolytic Anemia:

Name: Hemolytic Anemia 38 12 14
Anemia Hemolytic 12 29 52
Anemia, Hemolytic 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:583
ICD10 33 D55-D59
MeSH 42 D000743
NCIt 47 C34376
UMLS 69 C0002878

Summaries for Hemolytic Anemia

MalaCards based summary : Hemolytic Anemia, also known as anemia hemolytic, is related to spherocytosis, type 3 and stomatocytosis i, and has symptoms including icterus An important gene associated with Hemolytic Anemia is GPI (Glucose-6-Phosphate Isomerase), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Iron and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and b cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 71 Hemolytic anemia or haemolytic anaemia is a form of anemia due to hemolysis, the abnormal breakdown of... more...

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Congenital Hemolytic Anemia Autoimmune Hemolytic Anemia
Hemolytic Anemia Due to Band 3 Montefiore Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
id Related Disease Score Top Affiliating Genes
1 spherocytosis, type 3 31.7 SPTA1 SPTB
2 stomatocytosis i 31.3 ADAMTS13 HP
3 kernicterus 29.5 ANK1 SLC4A1 SPTA1 SPTB
4 autoimmune hemolytic anemia 12.5
5 hemolytic anemia due to hexokinase deficiency 12.4
6 warm antibody hemolytic anemia 12.3
7 congenital hemolytic anemia 12.3
8 hemolytic anemia due to g6pd deficiency 12.3
9 drug-induced autoimmune hemolytic anemia 12.2
10 hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency 12.2
11 hemolytic anemia due to adenylate kinase deficiency 12.2
12 hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency 12.2
13 hemolytic anemia due to triosephosphate isomerase deficiency 12.2
14 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.2
15 hemolytic anemia due to glutathione synthetase deficiency 12.2
16 hemolytic anemia due to glutathione peroxidase deficiency 12.1
17 congenital nonspherocytic hemolytic anemia 12.1
18 pyruvate kinase deficiency 12.0
19 mixed-type autoimmune hemolytic anemia 12.0
20 autoimmune hemolytic anemia, warm type 11.9
21 hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities 11.9
22 hemolytic anemia due to glutathione reductase deficiency 11.9
23 hereditary spherocytosis 11.8
24 hemolytic anemia due to erythrocyte adenosine deaminase overproduction 11.8
25 hemolytic anemia due to glyceraldehyde-3-phosphate dehydrogenase deficiency 11.8
26 hemolytic anemia due to band 3 montefiore 11.8
27 neonatal autoimmune hemolytic anemia 11.8
28 rh-null regulator type related hemolytic anemia 11.8
29 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 11.8
30 thrombotic thrombocytopenic purpura, familial 11.8
31 glucose phosphate isomerase deficiency 11.7
32 renal tubular acidosis, distal, ar 11.7
33 anemia, hemolytic, due to umph1 deficiency 11.7
34 evans' syndrome 11.7
35 cold agglutinin disease 11.7
36 glut1 deficiency syndrome 2 11.6
37 hemolytic-uremic syndrome 11.6
38 anemia, hemolytic, rh-null, regulator type 11.5
39 glucosephosphate dehydrogenase deficiency 11.4
40 erythrocytosis due to bisphosphoglycerate mutase deficiency 11.4
41 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.4
42 pyropoikilocytosis 11.3
43 thrombotic thrombocytopenic purpura 11.3
44 paroxysmal cold hemoglobinuria 11.3
45 phosphoglycerate kinase deficiency 11.3
46 glutathione synthetase deficiency 11.3
47 hemoglobinuria 11.1
48 favism 11.1
49 paroxysmal nocturnal hemoglobinuria 11.1
50 splenomegaly 11.1

Graphical network of the top 20 diseases related to Hemolytic Anemia:



Diseases related to Hemolytic Anemia

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:


icterus

MGI Mouse Phenotypes related to Hemolytic Anemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ADAMTS13 ANK1 CD59 EPB42 G6PD GPI
2 homeostasis/metabolism MP:0005376 9.8 PKLR RHAG SLC4A1 SPTA1 SPTB ADAMTS13
3 mortality/aging MP:0010768 9.44 ADAMTS13 ANK1 CD59 G6PD GCLC GPI

Drugs & Therapeutics for Hemolytic Anemia

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 472)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
2
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
3
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1 30652-11-0 2972
4
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 70-51-9 2973
5
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
6
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
7
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 127-07-1 3657
8
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 201530-41-8 5493381
9
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2 198153-51-4 5360545
12
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
14
Mannitol Approved, Investigational Phase 4,Phase 3 69-65-8 453 6251
15
Prilocaine Approved Phase 4 721-50-6 4906
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
17
Zinc Approved Phase 4,Phase 2,Phase 1 7440-66-6 32051 23994
18 Zinc sulfate Approved Phase 4,Phase 2,Phase 1 7733-02-0
19
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 2 466-99-9 5284570
20
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
21
Primaquine Approved Phase 4,Phase 3,Phase 1 90-34-6 4908
22
Dapsone Approved, Investigational Phase 4,Phase 3 80-08-0 2955
23
Basiliximab Approved, Investigational Phase 4,Phase 2 152923-56-3, 179045-86-4
24
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
25
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
27
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
28
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
29
Codeine Approved, Illicit Phase 4,Phase 1,Phase 2 76-57-3 5284371
30
Guaifenesin Approved, Vet_approved Phase 4,Phase 1,Phase 2 93-14-1 3516
31
Metformin Approved Phase 4,Early Phase 1 657-24-9 14219 4091
32
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
33
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2 6740-88-1 3821
34
Desogestrel Approved Phase 4 54024-22-5 40973
35
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
36
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
37
Heroin Approved, Illicit Phase 4 561-27-3 5462328
38
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 67-97-0 6221 10883523 5280795
39
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
42 Antacids Phase 4,Phase 1
43 Anti-Ulcer Agents Phase 4,Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
45
Proton pump inhibitors Phase 4,Phase 1
46 Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Iron Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
49 Vaccines Phase 4,Phase 3,Phase 2
50 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 868)
id Name Status NCT ID Phase
1 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4
2 Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major Unknown status NCT00103753 Phase 4
3 B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals Unknown status NCT01846923 Phase 4
4 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4
5 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Completed NCT00491179 Phase 4
6 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C Completed NCT00491244 Phase 4
7 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4
8 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4
9 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4
10 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4
11 Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events Completed NCT00346242 Phase 4
12 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed NCT01482091 Phase 4
13 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated Completed NCT01609192 Phase 4
14 Zinc Supplementation on Cellular Immunity in Thalassemia Major Completed NCT03117192 Phase 4
15 Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Completed NCT00733811 Phase 4
16 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
17 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed NCT00171301 Phase 4
18 This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4
19 Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Completed NCT02522104 Phase 4
20 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4
21 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4
22 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4
23 Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Completed NCT03095326 Phase 4
24 Post Hematopoietic Stem Cell Transplantation Completed NCT01610297 Phase 4
25 Combo Chelation Trial Completed NCT00901199 Phase 4
26 Efficacy Study in Removing Excess Iron From the Heart Completed NCT00105495 Phase 4
27 Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major Completed NCT00800761 Phase 4
28 Safety and Tolerability of Low Dose Primaquine Completed NCT02434952 Phase 4
29 Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection Completed NCT00707850 Phase 4
30 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4
31 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Completed NCT00867932 Phase 4
32 Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease Completed NCT00288600 Phase 4
33 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Recruiting NCT02594904 Phase 4
34 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Recruiting NCT02731157 Phase 4
35 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4
36 Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4
37 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4
38 Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial Recruiting NCT03032666 Phase 4
39 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Recruiting NCT02574403 Phase 4
40 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4
41 Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment Active, not recruiting NCT02149537 Phase 4
42 the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children Active, not recruiting NCT02674607 Phase 4
43 Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia Active, not recruiting NCT01709838 Phase 4
44 Mobile-Directly Observed Therapy on Adherence to Hydroxyurea Enrolling by invitation NCT02844673 Phase 4
45 Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4
46 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Enrolling by invitation NCT02614898 Phase 4
47 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Not yet recruiting NCT02984475 Phase 4
48 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Not yet recruiting NCT03178643 Phase 4
49 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
50 Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease Terminated NCT00115336 Phase 4

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemolytic Anemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: anemia, hemolytic

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

id Genetic test Affiliating Genes
1 Hemolytic Anemia 29

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

39
Testes, Liver, B Cells, T Cells, Bone, Kidney, Bone Marrow

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

(show top 50) (show all 1400)
id Title Authors Year
1
Autoimmune hemolytic anemia associated with babesiosis. ( 28405337 )
2017
2
A Rare Cause of Neonatal Hemolytic Anemia: Glutathione Synthetase Deficiency. ( 28267090 )
2017
3
Neonatal nonimmune hemolytic anemia. ( 27861255 )
2017
4
Immune Hemolytic Anemia (Paroxysmal Cold Hemoglobinuria) Preceding Burkitt Lymphoma in a 12-Year-Old Child. ( 27879544 )
2017
5
High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. ( 28233743 )
2017
6
A Case of Idiopathic Pulmonary Hemosiderosis Presenting With Signs and Symptoms Mimicking Hemolytic Anemia. ( 27918350 )
2017
7
Post-Babesiosis Warm Autoimmune Hemolytic Anemia. ( 28273010 )
2017
8
Simultaneous occurrence of autoimmune hemolytic anemia and pure red cell aplasia. ( 28090019 )
2016
9
Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation. ( 27429816 )
2016
10
Genetic diagnosis for congenital hemolytic anemia. ( 27725587 )
2016
11
IgG4-related Lung Disease Associated with Autoimmune Hemolytic Anemia: A Case Report and a Literature Review. ( 27580552 )
2016
12
"Clinical characteristics and outcome of patients with autoimmune hemolytic anemia (AIHA) uniformly defined as primary by a diagnostic work-up". ( 27059006 )
2016
13
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
14
Pitfalls of Treating Alcoholic Hepatitis: Recognizing Hemolytic Anemia in Zieve's Syndrome. ( 27125716 )
2016
15
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy. ( 27920704 )
2016
16
Risk factor analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in children. ( 27861376 )
2016
17
Autoimmune Hemolytic Anemia Induced by Adalimumab. ( 26984100 )
2016
18
Burkitt Lymphoma Preceded by Autoimmune Hemolytic Anemia due to Anti-D Antibody. ( 27523004 )
2016
19
Bilateral Prefoveal Sub-Internal Limiting Membrane Hemorrhage in Autoimmune Hemolytic Anemia. ( 27977840 )
2016
20
ATP11C is a major flippase in human erythrocytes and its defect causes congenital hemolytic anemia. ( 26944472 )
2016
21
Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization. ( 27158433 )
2016
22
Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. ( 26613837 )
2016
23
Retrospective study of reticulocyte indices as indicators of iron-restricted erythropoiesis in dogs with immune-mediated hemolytic anemia. ( 27034340 )
2016
24
Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant. ( 26841192 )
2016
25
Identification of Stages of Erythroid Differentiation in Bone Marrow and Erythrocyte Subpopulations in Blood Circulation that Are Preferentially Lost in Autoimmune Hemolytic Anemia in Mouse. ( 27870894 )
2016
26
Pure Red Cell Aplasia and Autoimmune Hemolytic Anemia Sequentially Occurring in a Patient with Large Granular T-lymphocytic Leukemia. ( 27250059 )
2016
27
Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances. ( 27382547 )
2016
28
Acquired and Congenital Hemolytic Anemia. ( 27252179 )
2016
29
Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients. ( 27821514 )
2016
30
Two Novel Missense Mutations and a 5bp Deletion in the Erythroid-Specific Promoter of the PKLR Gene in Two Unrelated Patients With Pyruvate Kinase Deficient Transfusion-Dependent Chronic Nonspherocytic Hemolytic Anemia. ( 26728349 )
2016
31
Recurrent Isolated Neonatal Hemolytic Anemia: Think About Glutathione Synthetase Deficiency. ( 27581854 )
2016
32
Dacie JV. Diagnosis and mechanism of hemolysis in chronic hemolytic anemia with nocturnal hemoglobinuria. ( 26823505 )
2016
33
Progressive Disseminated Histoplasmosis with Coomb's Positive Hemolytic Anemia in an Immunocompetent Host. ( 27759351 )
2016
34
Autoimmune Hemolytic Anemia in Individuals Aged 75 and Older: A Study of 10 Individuals. ( 27321629 )
2016
35
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. ( 27657651 )
2016
36
A 2-month-old boy with hemolytic anemia and reticulocytopenia following intravenous immunoglobulin therapy for Kawasaki disease: a case report and literature review. ( 28018448 )
2016
37
PIEZO1 gene mutation in a Japanese family with hereditary high phosphatidylcholine hemolytic anemia and hemochromatosis-induced diabetes mellitus. ( 26971963 )
2016
38
Cold autoimmune hemolytic anemia secondary to atypical pneumonia. ( 27597386 )
2016
39
Autoimmune Hemolytic Anemia Triggered by Infection with Human Parvovirus B19 after Total Abdominal Colectomy for Ulcerative Colitis. ( 26984090 )
2016
40
Pediatric Inflammatory Bowel Disease and Hereditary Hemolytic Anemia: A Retrospective Analysis. ( 27508516 )
2016
41
Hemolytic anemia with null PKLR mutations identified using whole exome sequencing and cured by hematopoietic stem cell transplantation combined with splenectomy. ( 27595284 )
2016
42
Autoimmune Hemolytic Anemia and Hodgkin's Disease: An Unusual Pediatric Association. ( 26904342 )
2016
43
Fatal warm autoimmune hemolytic anemia in a child due to IgM-type autoantibodies. ( 27273179 )
2016
44
Warm antibody hemolytic anemia-a rare presentation of neonatal lupus. ( 27516434 )
2016
45
Autoimmune Hemolytic Anemia in Children: Mayo Clinic Experience. ( 26925716 )
2016
46
Spur cell hemolytic anemia in liver failure. ( 27079310 )
2016
47
Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin. ( 27976566 )
2016
48
Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of 'chronic Lyme disease'. ( 27169474 )
2016
49
Portable microsystem integrates multifunctional dielectrophoresis manipulations and a surface stress biosensor to detect red blood cells for hemolytic anemia. ( 27647457 )
2016
50
Microangiopathic Hemolytic Anemia Due to ADAMTS-13 Loss in Idiopathic Systemic Capillary Leak Syndrome. ( 27622772 )
2016

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HBB NM_000518.4(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
2 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995

Expression for Hemolytic Anemia

Search GEO for disease gene expression data for Hemolytic Anemia.

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 AK1 ALDOA G6PD GCLC GPI GSS
2
Show member pathways
12.63 ALDOA G6PD GPI PGK1 PKLR
3
Show member pathways
11.77 ANK1 SPTA1 SPTB
4
Show member pathways
11.67 ALDOA G6PD GPI PGK1 PKLR
5
Show member pathways
11.65 ALDOA PGK1 PKLR
6
Show member pathways
11.34 ALDOA G6PD GPI
7
Show member pathways
10.98 HBB RHAG SLC4A1
8 10.81 ANK1 SPTA1 SPTB
9 10.55 PGK1 PKLR
10
Show member pathways
10.36 G6PD GPI
11 10 G6PD GPI PGK1

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.9 AK1 ALDOA CD59 G6PD GPI GSS
2 ficolin-1-rich granule lumen GO:1904813 9.67 ALDOA GPI HBB
3 tertiary granule lumen GO:1904724 9.5 ALDOA HBB HP
4 intrinsic component of the cytoplasmic side of the plasma membrane GO:0031235 9.46 SPTA1 SPTB
5 endocytic vesicle lumen GO:0071682 9.43 HBB HP
6 spectrin GO:0008091 9.37 SPTA1 SPTB
7 haptoglobin-hemoglobin complex GO:0031838 9.26 HBB HP
8 cortical cytoskeleton GO:0030863 9.13 EPB42 SLC4A1 SPTA1
9 spectrin-associated cytoskeleton GO:0014731 8.8 ANK1 SPTA1 SPTB
10 cytosol GO:0005829 10.22 AK1 ALDOA ANK1 G6PD GCLC GPI
11 extracellular space GO:0005615 10.02 ADAMTS13 ALDOA CD59 GPI HBB HP

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.89 ALDOA CD59 GPI HBB HP
2 ER to Golgi vesicle-mediated transport GO:0006888 9.71 ANK1 CD59 SPTA1 SPTB
3 actin filament capping GO:0051693 9.54 SPTA1 SPTB
4 regulation of blood vessel size GO:0050880 9.52 GCLC HBB
5 glutathione biosynthetic process GO:0006750 9.51 GCLC GSS
6 gluconeogenesis GO:0006094 9.5 ALDOA GPI PGK1
7 erythrocyte maturation GO:0043249 9.48 EPB42 G6PD
8 response to xenobiotic stimulus GO:0009410 9.46 GCLC GSS
9 glucose 6-phosphate metabolic process GO:0051156 9.43 G6PD GPI
10 bicarbonate transport GO:0015701 9.43 HBB RHAG SLC4A1
11 cellular ion homeostasis GO:0006873 9.37 RHAG SLC4A1
12 response to cadmium ion GO:0046686 9.33 GCLC GPI GSS
13 glycolytic process GO:0006096 9.26 ALDOA GPI PGK1 PKLR
14 canonical glycolysis GO:0061621 8.92 ALDOA GPI PGK1 PKLR

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 magnesium ion binding GO:0000287 9.56 GCLC GSS NT5C3A PKLR
2 structural constituent of cytoskeleton GO:0005200 9.26 ANK1 EPB42 SPTA1 SPTB
3 hemoglobin binding GO:0030492 9.16 HBB HP
4 ankyrin binding GO:0030506 8.8 RHAG SLC4A1 SPTB

Sources for Hemolytic Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....